Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T00:16:13.169Z Has data issue: false hasContentIssue false
  • English
  • Français

What is the link between the antidepressants, the transcranial magnetic stimulation and the peripheral vascular endothelial growth factor?

Published online by Cambridge University Press:  01 September 2022

J. Lazáry ,
M. Elemery ,
S. Kiss ,
L. Pogany  and
G. Faludi
J. Lazáry*
Affiliation:
Nyírő Gyula National Institute of Psychiatry and Addictions, Department Of Psychiatry, Budapest, Hungary
M. Elemery
Affiliation:
Semmelweis University, Janos Szentagothai Neuroscience Doctoral School, Budapest, Hungary
S. Kiss
Affiliation:
Semmelweis University, Janos Szentagothai Neuroscience Doctoral School, Budapest, Hungary
L. Pogany
Affiliation:
National Institute of Mental Health, Neurology and Neurosurgery, Department Of Biological Psychiatry, Budapest, Hungary
G. Faludi
Affiliation:
Semmelweis University, Janos Szentagothai Neuroscience Doctoral School, Budapest, Hungary
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Vascular endothelial growth factor (VEGF) has been implicated in mediating the effect of antidepressants (AD) and electroconvulsive therapy on depression since it plays a significant role in the neurogenesis. However, the serum VEGF level has not been investigated so far in association with rTMS treatment in patients with major depressive disorder (MDD).

Objectives

The aim of our study was to compare the effect of the antidepressants and of the repetitive transcranial magnetic stimulation on the serum vascular endothelial growth factor and its association with the responsiveness to the treatments.

Methods

A dataset of 50 patients with TRD who were treated with AD (n=33) and bilateral rTMS for 2x5 days (n=17) was analysed (sample ’rTMS&AD’). Montgomery-Asberg Depression Scale (MADRS) was used for monitoring the symptom changes. The serum VEGF levels and symptoms were assessed on the first (V1), on the 14th (V2) and on the 28th day (V3). The VEGF levels were measured by ELISA assay.

Results

The baseline VEGF levels were significantly higher in non-responders both in the rTMS&AD (p=0.04) and AD samples (p=0.02) compared to responders. The MADRS reduction and the changes in VEGF levels between V1 and V3 were significantly associated in responders only in the AD&rTMS sample (p=0.03). The baseline VEGF level has been proven as a significant predictive factor of treatment response in the total sample (p=0.018).

Conclusions

The baseline VEGF level can be a predictive factor to be a non-responder to different treatments. Change of the VEGF level is associated with the improvement of depressive symptoms only due to rTMS.

Disclosure

This study was supported by the FK 131315 grant of the National Research, Development and Innovation Office, Hungary. Authors declare no conflict of interest.

Keywords

depressionrTMSnon-responderstreatment resistant depressionVEGF
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S260
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.